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advanced stage IV neuroblastoma resistant to 3-5 chemotherapeutic agents. VM-26 w?s given as a 1 hour intravenous infusion on a weekly schedule of 130 mglm2 x 3. 150 mglm2 x 3 . then 180 mg/m2 until progression of disease. Of 12 evaluable patients. one had a complete response of 211 days duration, four had partial responses of 21+. 21+. 58 and 78 days duration. four had either static disease or transient subjective responses, and three had no response. Dose-limiting toxicity was hematologic, with severe leukopenia occurring in five patients and thrombocytopenia in four patients. The toxicity was temporary in that most patients were able to tolerate the scheduled Gosage escalations.
A response rate of 42% is taken as evidence for further trials of this drua in neuroblastoma. Hematological parameters were studied in 33 infants with sickle cell disease from birth to 2 yearsot age. The hemoglobin was below normal for age as early as 6 weeks and remained low thereafter (average 8 . 7 gmr). Significant reticulocytosis was noticed a s early as one month of age, and by three months,it averaged 7.6%. Hb F concentration in these infants declined more slowly than in normal infants and at 6 months of age averaged 25.6%; at 1 year the Hb F concentration was about 20%. The intracellular distribution of the Hb F (by the Betke-Kleihauer technique) was heterogeneous a t all ages. Even in infants less than 3 weeks of age, "ghost"cel1s containing no Hb F (presumably therefore containing only Hb S) were seen. Our data indicate that in newborn infants with Hb S (as in those with Hb A) a population of cells containing little or no Hb F is present even when there is a high concentration of Hb F in the blood. In infants with Hb S, sickling and hemolysis of this vulnerable cell population would explain the uniform early development of hemolytic anemia by 6 weeks of age. (1) the ability of 1:100 to 1:5000 dilutlms to shorten the unactivated partial thrcmboplastin timc (PPl') of n o d and hemphllic plasm in vitro, and (2) transient shortening of patients' pmthtwnbin time ard FIT after cach dose. l h r e was no correlation between tixse laboratory parameters Of ~ccelerated coagulation and cessation of bleedlrt;. Therefore, efficacy of FCC must be j u W primarily by clinical response rather than by laboratory tests demonstratinp: activation of coagulation. The ZSR has certnfn technical advantages over the erythrocvte seditrentaticn rate (ESP), and is not influenced hv the presence of oneria. A study was undertaken tc efitoblist normal values for the ZSR in fnfonts and children, and to compare the diagnostic utility of the 7,SR as oppcsed to the ESR in children believed to hove activr inflammatory processes. The noma1 values for the ZSR in infants and younger children (mean t2SD) were sipnificentlv lover than in the older age group: AGE ZSR <2 G. 47.3'f 7.8 28 The ESP. showed o similar, although not statistically significant trend. TFere were 6 chjldren considered normal who, however, ha? increafied ESRs but nornal ZSRn. 416 were anemic, and nav therefrrc Iiav~ had folselv elevated ESR values. Among the 70 tefits obtnfned on children believef to have clinically active fnflamtorp pracessrfi. 2/70 (3X) had normal ?SRs and ESRs. 6/70 ( 9 3 had increased ESRs with concomitantlv normal ZSRs, whereas 6/70 (92) had normal ESRs with elevated 7SRs. These findings suggest that the ZSR is comparable to the ESR as an index of disease, and is recommended as a technically superior substitute for the I!SR in infants and children.
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